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In an open-label, single-center phase 1 pharmacokinetic study in healthy subjects who received lumacaftor (LUM) in combination with
ivacaftor (IVA), review of spirometry data showed a transient decline in percent predicted forced expiratory volume in 1 s (ppFEV1) within 4 h of
drug administration. An additional cohort of healthy subjects with normal baseline ppFEV1 values was studied to evaluate the ppFEV1 response to
LUM/IVA administration and assess the effect of long-acting bronchodilators (LABDs) and short-acting bronchodilators (SABDs) on ppFEV1
response. The ppFEV1 decline observed at 4 h was attenuated following administration of an LABD and reversed following administration of an
SABD. Concomitant administration of LUM/IVA with bronchodilators was well tolerated. These data show that a transient decline in ppFEV1 was
observed in healthy subjects following administration of LUM/IVA combination therapy, which can be ameliorated with LABDs or SABDs.
© 2016 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
In 2 phase 3 studies, treatment with the combination of
lumacaftor (LUM) and ivacaftor (IVA) resulted in clinically
meaningful improvements in lung function, rate of pulmonary
exacerbations and nutritional status in patients aged 12 years
or older with cystic fibrosis (CF) who were homozygous for
the F508del-CFTR mutation [1]. LUM/IVA was generally well
tolerated; however, the incidence of certain respiratory adverse
events (AEs), including dyspnea and chest tightness, was higher in
LUM/IVA-treated patients than placebo-treated patients. These
AEs were often associated with initiation of therapy and generally
resolved within the first few weeks of treatment [1]. In a phase 2
study of patients with CF who had an F508del-CFTR mutation,
dose-dependent reductions in percent predicted forced expiratory
volume in 1 s (ppFEV1) were observed during the 28-day period of
LUM monotherapy [2]. Review of spirometry data from an
open-label, single-center phase 1 pharmacokinetic study in healthy⁎ Corresponding author.
E-mail address: gautham_marigowda@vrtx.com (G. Marigowda).
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administration of LUM/IVA combination therapy. To better
understand this decline, a cohort was added to the latter study to
evaluate ppFEV1 response within 4 h of LUM/IVA administration
and assess the effect of long-acting bronchodilators (LABDs) and
short-acting bronchodilators (SABDs) on ppFEV1 response.
2. Methods
Healthy male and female volunteers aged 18 to 55 years with
ppFEV1 80 or higher, body mass index 18 to 31 kg/m
2 and body
weight more than 50 kg were eligible; those with a history of
regular alcohol consumption, smoking and bronchodilator use
within the previous 28 days were excluded. Participants were
randomized to 1 of 4 dosing sequences (1:1:1:1), each of which
included 3 dosing periods (period 1: days −2 to 2; period 2: days 6
to 9; period 3: days 13 to 16). Once during each dosing period on
days 1, 8 and 15, LUM 200 mg was administered in combination
with IVA 250 mg orally in the morning. The peak concentrations
in healthy subjects administered LUM 200 mg/IVA 250 mg were
projected to be comparable to the peak concentrations in patientsystic Fibrosis Society. This is an open access article under the CC BY-NC-ND
iduals receiving lumacaftor/ivacaftor combination therapy, J Cyst Fibros (2016),
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Figs. 1 and 2, an SABD (albuterol 2.5 mg or ipratropium 0.5 mg)
was administered by inhalation via nebulizer during each dosing
period (after the 4-h spirometry assessment) and an LABD
(indacaterol 75 μg or tiotropium 18 μg) was administered via
inhalation in dosing periods 2 and 3 (12 h prior to and 12 h
after LUM/IVA administration); spirometry assessments were
performed throughout the study.
The primary outcome measure was the absolute change in
ppFEV1 from before to 4 h after LUM/IVA administration.
Safety was assessed by the incidence of treatment emergent
AEs, vital signs, clinical laboratory tests, electrocardiograms,
spirometry and physical examinations. A mixed model for
repeated measures was used to evaluate the overall effect
of LABDs by comparing the absolute change in ppFEV1 from
before LUM/IVA to 4 h post LUM/IVA in the presence and
absence of LABDs. The model included sequence and treatment
(albuterol + ipratropium, indacaterol, tiotropium) as fixed
effects, period baseline ppFEV1 as a covariate and subject nested
within sequence as a random effect. Data for ppFEV1 were
pooled for administration of an SABD (albuterol, ipratropium)
and an LABD (indacaterol, tiotropium).3. Results
A total of 26 participants was enrolled; 24 (92.3%) completed
the study and 2 (7.7%) withdrew consent and were discontinued
after dosing period 1. Baseline characteristics were well balanced80
85
90
95
100
105
Screen Day
−2
0h 2h 4h 5h 8h Pre 2h
Pe
rc
en
t p
re
di
ct
ed
 F
EV
1 
(M
ea
n ±
SE
)
SABD
LUM/IV
Percent predicted FEV1
Mean
Absolute difference
Pre
96.6
2h
94.2
−2.3
Day −1 
0h 2h 4h 5h 8h Pre 2hTiming of drug administration 
+ spirometry assessments
SABD LUM/IVA
Period 1
Day −1 
Fig. 1. Percent predicted FEV1 before and after LUM/IVA administration in the abse
indicate standard error. FEV1, forced expiratory volume in 1 s; LUM/IVA, lumacaf
Please cite this article as: MarigowdaG, et al, Effect of bronchodilators in healthy indiv
http://dx.doi.org/10.1016/j.jcf.2016.11.001for participants in each dosing sequence. The mean age (SD) was
36.5 (10.5) years and mean ppFEV1 (SD) was 96.6 (14.8).
We observed a transient decline in ppFEV1 after a single
dose of LUM/IVA (mean absolute change [SD] on day 1 at 4 h
was −4.1 [5.6] percentage points). The absolute change in
ppFEV1 for each individual subject is shown in Fig. 3. The
decline in ppFEV1 was rapidly reversed following
administration of an SABD (Fig. 1). The mean (SD) difference
in absolute change in ppFEV1 from 4 h to 5 h post LUM/IVA
following administration of an SABD in the absence of an
LABD was 3.8 (5.8) percentage points (p = 0.003); similar
results were observed with beta agonists and anticholinergics
(4.0 [5.5] percentage points for albuterol and 3.5 [6.3]
percentage points for ipratropium). Moreover, when an
LABD was administered 12 h before LUM/IVA, the decline
in ppFEV1 was attenuated (Fig. 2). The mean absolute change
(SD) was −1.4 (4.1) percentage points on days 8 and 15
(average) at 4 h post LUM/IVA. The least squares (LS) mean
(SE) difference for attenuation of the decline in ppFEV1 in
the presence of all LABDs vs in the absence of LABDs was
2.9 (1.4) percentage points (p = 0.046); findings were similar
for beta agonists and anticholinergics (LS mean [SE]: 3.1
[1.6] percentage points for indacaterol and 2.8 [1.6]
percentage points for tiotropium). As shown in Fig. 2, an
SABD administered 4 h post LUM/IVA in the presence of an
LABD led to further improvement in ppFEV1.
Overall, 11 participants (42.3%) reported AEs, all of which
were mild (n = 9) or moderate (n = 2) in severity. AEs
occurring in more than one participant included oropharyngealDay 1 Day 2 (Time matched)
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2 (7.7%). One AE of dyspnea was reported and considered
possibly related to study drug; it occurred within 1 day of
initiating treatment, was mild in severity and resolved. The
transient decline in ppFEV1 observed after LUM/IVA adminis-
tration was not reported as an AE. No clinically relevant trends
were observed in laboratory tests or vital signs.–30
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Our findings reveal that administration of LUM/IVA resulted
in a transient decline in ppFEV1 in healthy subjects with normal
baseline ppFEV1 values, a response attenuated by pre-treatment
with an LABD and reversed with an SABD. These results suggest
that bronchoconstriction could contribute to the occurrence ofhours post dose on day 1
hodilator (day 1). Waterfall plot showing the absolute change in ppFEV1 at 4 h
ta for an individual subject. LUM/IVA, lumacaftor/ivacaftor; ppFEV1, percent
iduals receiving lumacaftor/ivacaftor combination therapy, J Cyst Fibros (2016),
4 G. Marigowda et al. / Journal of Cystic Fibrosis xx (2016) xxx–xxxcertain respiratory AEs (i.e., dyspnea and chest tightness) observed
in some CF patients upon initiation of LUM/IVA [1]. Recent
evidence suggests that loss of CF transmembrane conductance
regulator (CFTR) function may play a role in the airway smooth
muscle dysfunction that is common in patients with CF [4];
however, it appears that CFTR modulation may ameliorate this.
Using a porcine model, CFTR was found to localize to the
sarcoplasmic reticulum compartment of airway smooth muscle,
where it regulates Ca2+ reuptake and airway smooth muscle
basal tone. Loss of CFTR was found to increase basal tone,
while CFTR potentiation with IVA was found to reduce airway
reactivity in that study [4]. Furthermore, in a phase 3 clinical
study in patients with CF and the G551D-CFTR mutation, there
was not an increased incidence of respiratory AEs (i.e., dyspnea
and chest tightness) with IVA monotherapy [5]. These findings
suggest that a potential bronchoconstrictive response does not
occur with IVA monotherapy. The apparent bronchoconstrictive
effect with LUM is thus likely an off-target effect.
Importantly, LUM/IVA was well tolerated when adminis-
tered concomitantly with bronchodilators in this study. Future
studies to evaluate whether bronchodilator pre-treatment would
ameliorate the occurrence of dyspnea and/or chest tightness in
some CF patients beginning treatment with LUM/IVA may be
warranted.
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